ANI Pharmaceuticals completes acquisition of Alimera Sciences

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has finalized the acquisition of Alimera (NASDAQ:ALIM) Sciences, Inc., a move that significantly expands its ophthalmology portfolio. The transaction was completed on Monday, with ANI Pharmaceuticals, now the parent company, absorbing Alimera as a wholly-owned subsidiary.

Under the terms of the agreement, shareholders of Alimera will receive $5.50 in cash for each share they own, plus one contingent value right (CVR). These CVRs grant the right to additional cash payments if certain revenue milestones are achieved in fiscal years 2026 and 2027 from sales of ILUVIEN® and YUTIQ®, two products now under ANI's umbrella.

ANI Pharmaceuticals financed the cash consideration of the deal through a $325 million borrowing under a senior secured credit agreement with JPMorgan Chase (NYSE:JPM) Bank, N.A., and from its available cash on hand.

The CVR arrangement stipulates that if net revenues exceed $140 million in 2026 or $160 million in 2027 for the specified products, CVR holders will receive a proportionate cash payment. The precise amount will depend on the extent to which the actual revenues surpass the defined thresholds.

Moreover, certain outstanding Alimera equity awards were converted into rights to receive CVRs. Alimera stock options with an exercise price less than the per-share cash consideration were also exchanged for CVRs, while options with an exercise price above the cash consideration but below the total consideration may still receive a payment contingent upon the CVRs' payout.

ANI Pharmaceuticals has committed to using diligent efforts to achieve the milestones as outlined in the CVR agreement, with the Rights Agent and holders of a significant percentage of the CVRs having certain audit and enforcement rights.

This strategic acquisition is expected to bolster ANI's position in the specialty pharmaceuticals market, particularly in the area of eye health. The integration of Alimera's products into ANI's portfolio is a step towards the company's growth and diversification goals.

The information provided is based on a recent SEC filing by ANI Pharmaceuticals, Inc.

In other recent news, ANI Pharmaceuticals demonstrated a robust second quarter in 2024, marking an 18% rise in revenues to $138 million compared to the same period in 2023. The surge in revenue was primarily driven by the company's rare disease asset, the purified Cortrophin gel, which saw a 102% increase in revenue, and a solid performance in the generics business, which grew by 17%. Despite a net loss of $2.7 million for the quarter, ANI Pharmaceuticals has revised its full-year net revenue guidance to $540 million to $560 million.

ANI Pharmaceuticals also recently finalized the acquisition of Alimera Sciences , a move expected to bolster its rare disease business with a new global commercial ophthalmology franchise. This acquisition is anticipated to be immediately accretive to ANI Pharmaceuticals and is projected to complement its existing Cortrophin Gel in ophthalmology. The deal also provides ANI Pharmaceuticals with a global footprint, potentially expanding its business development opportunities.

Meanwhile, H.C. Wainwright has maintained a Buy rating for ANI Pharmaceuticals, while Truist Securities downgraded the company's stock rating from Buy to Hold, citing concerns regarding the delayed closure of ANI's acquisition of Alimera and potential issues discovered during due diligence. Despite these concerns, ANI Pharmaceuticals remains optimistic about its future growth, particularly with the acquisition of Alimera Sciences.

Finally, ANI Pharmaceuticals has launched a new generic medication, Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, for treating symptoms associated with cough and cold. This marks the 14th new product launch for the company this year, contributing to the growth of their Generics business.

InvestingPro Insights

ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) recent acquisition of Alimera Sciences is a strategic move that positions the company for potential growth in the ophthalmology sector. In light of this development, insights from InvestingPro reveal that ANI Pharmaceuticals is trading at a low P/E ratio relative to near-term earnings growth, with a current P/E ratio of 36.98. This suggests that the market may not have fully factored in the company's growth prospects. Additionally, analysts predict that the company will be profitable this year, which could be a positive sign for investors following the acquisition.

From a financial health perspective, ANIP's liquid assets exceed its short-term obligations, indicating a stable liquidity position that could support the integration of Alimera's products. Moreover, ANI Pharmaceuticals operates with a moderate level of debt, which is important as the company has financed the acquisition through borrowing.

InvestingPro Tips also highlight that ANI Pharmaceuticals has been profitable over the last twelve months, with a reported net income growth expected this year. This profitability, coupled with the company's strong free cash flow yield as indicated by its valuation, may provide the financial flexibility needed to achieve the revenue milestones set for the newly acquired products ILUVIEN® and YUTIQ®.

For investors seeking more in-depth analysis, there are 9 additional InvestingPro Tips available for ANI Pharmaceuticals, which can be accessed through the InvestingPro platform. These tips could further guide investment decisions in the context of ANI's latest strategic acquisition and overall market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.